I don't think it's gimmicky. I think it's a tremendous statement of confidence in our program, ... In the world of interventional cardiology where patients are elderly, diseased, suffering, we don't really think of ourselves as providing gimmicks.

257

What we get is diversification for Boston Scientific and growth, and we get that through CRM. Clearly, CRM is the key asset here.

226

We see real flaws in the method. We're not dealing with a system that has a lot of precedent and has a lot of transparency.

212

We are very confident in our proposal. We think the (recall) issues are very manageable.

160

If you want me to comment on accelerating share decline, I guess I would have to say we don't see it.

100